15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 12 firms covering Summit Therapeutics PLC, 5 rate it Buy or better, 7 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $11.90 to $40.00 (about 3.4x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $26.63 sits 54% above the current $17.28. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.25 next quarter toward $-0.88 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS12 ratings
Moderate Buy
Strong Buy00%
Buy542%
Hold758%
Sell00%
Strong Sell00%
Based on 12 analysts giving stock ratings to Summit Therapeutics PLC.
As of Sep, 5 of 12 firms rate SMMT a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SMMT EPS & revenue forecast
EPS · NEXT QUARTER
$-0.25
Range $-0.54 – $-0.09 · 11 analysts · +18% YoY
Next period, 11 analysts expect Summit Therapeutics PLC to earn $-0.25 a share (range $-0.54 – $-0.09), versus $-0.21 a year earlier. Full-year consensus is $-0.86, growing to $-0.88 the year after.
REVENUE · NEXT QUARTER
$3.0M
Range $0 – $11.3M · 11 analysts
Revenue is expected to reach $3.0M (range $0 – $11.3M). Full-year consensus is $2.9M, rising to $41.7M next year.
Top analysts covering Summit Therapeutics PLC
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SMMT.
#1
Mitchell Kapoor
HC Wainwright & Co. · Rank #193
Hold
No targeton SMMT
Overall win rate
34%
+ Follow
#2
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$40.00+131.5% to target
Overall win rate
41%
+ Follow
#3
Daina Graybosch
Leerink Partners · Rank #304
Hold
$13.00-24.8% to target
Overall win rate
40%
+ Follow
#4
Reni J. Benjamin
JMP Securities · Rank #366
Buy
$40.00+131.5% to target
Overall win rate
32%
+ Follow
#5
Etzer Darout
Barclays
Hold
$18.00+4.2% to target
Coverage
—
+ Follow
SMMT stock forecast FAQ
What is SMMT's average 12-month price target?+
The 10 analysts with a live target average $26.63 for Summit Therapeutics PLC over the next 12 months, ranging from a $40.00 high to a $11.90 low.
Is SMMT stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 12 analyst ratings, 5 are Buy or Strong Buy, 7 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SMMT?+
The Street-high target is $40.00 (Citizens), and the Street-low is $11.90 (Bernstein). The average of all 10 active targets is $26.63.
How many Wall Street analysts cover SMMT?+
12 analysts have an active rating on Summit Therapeutics PLC, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering SMMT?+
Among analysts who currently cover SMMT, Mitchell Kapoor of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #193). Their current call is Hold.
What is Summit Therapeutics PLC's projected EPS for next quarter?+
The consensus estimate is $-0.25 per share (range $-0.54 – $-0.09) across 11 analysts. Full-year EPS is projected at $-0.86, rising to $-0.88 the following year.
How much revenue is Summit Therapeutics PLC expected to report next quarter?+
Consensus revenue is $3.0M (range $0 – $11.3M). Full-year revenue is projected at $2.9M, growing to $41.7M next year.
Have analysts been upgrading or downgrading SMMT lately?+
As of Sep, 5 of 12 firms rate SMMT a Buy (7 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SMMT calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
